<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">levodopa</th>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Brand Names</td>
</tr>
<tr>
<td class="label">Immediate Release</td>
<td>Sinemet, Madopar</td>
</tr>
<tr>
<td class="label">Controlled Release</td>
<td>Sinemet CR, Madopar HBS</td>
</tr>
<tr>
<td class="label">Extended Release</td>
<td>Rytary (IPX066)</td>
</tr>
<tr>
<td class="label">Inhaled Powder</td>
<td>Inbrija</td>
</tr>
<tr>
<td class="label">Intestinal Gel</td>
<td>Duodopa/Duopa</td>
</tr>
<tr>
<td class="label">Subcutaneous Infusion</td>
<td>Vyalev (foslevodopa)</td>
</tr>
</table>
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">levodopa</th>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Brand Names</td>
</tr>
<tr>
<td class="label">Immediate Release</td>
<td>Sinemet, Madopar</td>
</tr>
<tr>
<td class="label">Controlled Release</td>
<td>Sinemet CR, Madopar HBS</td>
</tr>
<tr>
<td class="label">Extended Release</td>
<td>Rytary (IPX066)</td>
</tr>
<tr>
<td class="label">Inhaled Powder</td>
<td>Inbrija</td>
</tr>
<tr>
<td class="label">Intestinal Gel</td>
<td>Duodopa/Duopa</td>
</tr>
<tr>
<td class="label">Subcutaneous Infusion</td>
<td>Vyalev (foslevodopa)</td>
</tr>
</table>
Levodopa (L-DOPA, L-3,4-dihydroxyphenylalanine) is the metabolic precursor to [dopamine](/entities/dopamine) and remains the most effective pharmacological treatment for [Parkinson's Disease](/diseases/parkinsons-disease) more than five decades after its introduction [@levodopa2025]. First synthesized by Casimir Funk in 1911 and later pioneered as a clinical therapy by Oleh Hornykiewicz and George Cotzias in the 1960s, levodopa revolutionized the management of Parkinson's Disease by directly addressing the core neurochemical deficit: the progressive loss of dopaminergic neurons in the [substantia nigra](/brain-regions/substantia-nigra) pars compacta [@levodopa] [@levodopaa] [@levodopa2025]. Unlike dopamine itself, levodopa crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1), making it suitable for oral administration. Once in the brain, levodopa is decarboxylated to dopamine by aromatic L-amino acid decarboxylase (AADC), replenishing depleted dopamine stores in the [striatum](/brain-regions/striatum) and restoring motor function [@levodopa] [@adverse2023] [@frontiers2025].
Levodopa is almost universally co-administered with a peripheral decarboxylase inhibitor -- carbidopa (in the United States) or benserazide (in Europe) -- which blocks the premature conversion of levodopa to dopamine in the peripheral circulation [@therapeutic2024]. This co-administration increases the bioavailability of levodopa to the brain from approximately 5-10% to over 30%, while dramatically reducing peripheral side effects such as nausea, vomiting, and orthostatic hypotension [@levodopa] [@carbidopa]. Today, carbidopa/levodopa (marketed as Sinemet, Rytary, Stalevo, and others) is prescribed to virtually every patient with Parkinson's Disease at some point during their illness and is listed on the World Health Organization's Model List of Essential Medicines.
The primary therapeutic mechanism of levodopa is straightforward: it serves as substrate for the enzyme AADC (also called DOPA decarboxylase), which catalyzes its conversion to dopamine within surviving nigrostriatal terminals and, to a lesser extent, within serotonergic neurons and glial cells. The newly synthesized dopamine is then packaged into synaptic vesicles and released into the synaptic cleft, where it activates postsynaptic D1 and D2 dopamine receptors on striatal medium spiny neurons [@levodopa] [@levodopa2025].
In the healthy brain, dopaminergic terminals in the [basal ganglia](/brain-regions/basal-ganglia) provide tonic, finely regulated dopamine release essential for the initiation and execution of voluntary movement. In Parkinson's Disease, the progressive degeneration of substantia nigra neurons leads to striatal dopamine depletion exceeding 60-80% before clinical symptoms manifest. Levodopa compensates for this deficit, restoring the balance between the direct (D1-mediated, movement-facilitating) and indirect (D2-mediated, movement-inhibiting) pathways of the basal ganglia motor circuit [@levodopa2025].
Levodopa is rapidly absorbed from the proximal small intestine and has a short plasma half-life of approximately 60-90 minutes. Its absorption is influenced by gastric emptying rate, dietary protein (large neutral amino acids compete for the same LAT1 transporter), and gut motility -- all of which can be altered in Parkinson's Disease due to autonomic dysfunction [@levodopa]. Once absorbed, levodopa undergoes extensive first-pass metabolism. Without a decarboxylase inhibitor, over 95% is converted to dopamine peripherally. The addition of carbidopa (at doses of 75 mg/day or greater) effectively inhibits peripheral AADC, allowing more levodopa to reach the central nervous system [@carbidopa].
Levodopa is also metabolized by catechol-O-methyltransferase ([COMT](/entities/comt)) to 3-O-methyldopa, and by monoamine oxidase (MAO) after its conversion to dopamine. This provides the pharmacological rationale for adjunctive [COMT inhibitors](/therapeutics/comt-inhibitors) (entacapone, opicapone, tolcapone) and [MAO-B inhibitors](/therapeutics/mao-b-inhibitors) (rasagiline, selegiline, safinamide), which extend levodopa's half-life and smooth out fluctuations in plasma levels [@update2024].
Standard carbidopa/levodopa immediate-release (IR) tablets (Sinemet) are available in multiple strength ratios (10/100, 25/100, 25/250 mg). They provide rapid onset of action (30-60 minutes) but relatively short duration of effect (3-5 hours), requiring multiple daily doses. Immediate-release formulations remain the backbone of levodopa therapy and are the most widely prescribed [@levodopa].
Controlled-release (CR) formulations (Sinemet CR) were developed to provide smoother plasma levels and longer duration. However, their erratic absorption and lower bioavailability (~70% compared to IR) have limited their widespread adoption as monotherapy. More recently, IPX066 (Rytary) was developed as an extended-release capsule containing both immediate-release and extended-release beads, providing more consistent plasma levels and reducing OFF time compared to standard IR formulations [@levodopaa].
Carbidopa/levodopa intestinal gel (Duopa, marketed as Duodopa outside the United States) delivers a continuous infusion of levodopa suspension directly into the jejunum via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube connected to a portable pump. This bypasses the variable gastric emptying seen in Parkinson's Disease and provides remarkably stable plasma levodopa concentrations, significantly reducing both OFF time and dyskinesia in advanced patients [@levodopaa].
Foslevodopa/foscarbidopa (Vyalev) is a phosphorylated prodrug formulation designed for continuous subcutaneous infusion via a wearable pump. Approved in 2024, it provides an alternative to intestinal gel infusion that avoids the need for surgical PEG-J placement while still delivering continuous levodopa exposure [@update2024].
Levodopa inhalation powder (Inbrija) is a rescue formulation for intermittent treatment of OFF episodes. Inhaled levodopa is absorbed rapidly through the pulmonary vasculature, achieving peak plasma levels within 10-30 minutes -- faster than oral formulations -- making it useful for patients experiencing sudden, unpredictable OFF periods [@levodopaa].
As Parkinson's Disease progresses and dopaminergic terminals continue to degenerate, the capacity of surviving neurons to store and regulate dopamine release diminishes. Patients become increasingly dependent on exogenous levodopa, and the clinical benefit of each dose begins to wane before the next dose takes effect -- a phenomenon known as "wearing off" or end-of-dose deterioration. Wearing off typically begins 2-5 years after levodopa initiation and eventually affects approximately 50-80% of patients [@levodopainduced] [@levodopainduceda].
The underlying pathophysiology involves both presynaptic and postsynaptic changes. Presynaptically, the loss of dopaminergic storage capacity means that striatal dopamine levels increasingly mirror the fluctuating plasma levodopa concentrations, producing pulsatile stimulation of dopamine receptors. Postsynaptically, chronic intermittent dopamine receptor stimulation induces maladaptive plasticity in striatal medium spiny neurons, altering gene expression and intracellular signaling cascades [@levodopa2025].
Levodopa-induced dyskinesia (LID) represents the other major motor complication of long-term therapy. Dyskinesias are involuntary, hyperkinetic movements -- typically choreiform or dystonic -- that occur in temporal relation to levodopa dosing. Peak-dose dyskinesias are the most common subtype, occurring when plasma levodopa (and therefore striatal dopamine) levels are highest. Diphasic dyskinesias occur during the rising and falling phases of the levodopa cycle, while OFF-period dystonia typically manifests as painful foot or leg cramping during low dopamine states [@levodopainduced].
The pathogenesis of LID involves pulsatile stimulation of denervated dopamine receptors, leading to downstream changes in striatal plasticity. Key molecular mechanisms include dysregulation of the D1 receptor signaling cascade involving [GSK3-beta](/entities/gsk3-beta), upregulation of the DeltaFosB transcription factor, aberrant [NMDA receptor](/entities/nmda-receptor) signaling, and altered activity of [CDK5](/entities/cdk5) and extracellular signal-regulated kinase (ERK) pathways. Serotonergic neurons in the raphe nuclei also contribute by converting levodopa to dopamine in an unregulated manner ("false transmitter" hypothesis), producing non-physiological dopamine release peaks [@levodopainduced] [@levodopainduceda].
Several strategies are employed to manage motor fluctuations and dyskinesia:
Levodopa's effects extend beyond motor symptoms. Non-motor side effects include:
A long-standing debate in Parkinson's Disease therapeutics concerned whether levodopa should be delayed as long as possible to prevent motor complications, or initiated early for optimal symptomatic benefit. The landmark ELLDOPA trial (2004) and subsequent PD MED trial demonstrated that early levodopa use does not accelerate disease progression and provides superior quality of life compared to dopamine agonist-first strategies. Current movement disorder society guidelines now generally support early levodopa use when symptoms warrant treatment, with attention to optimizing dose and formulation to minimize long-term motor complications [@levodopa2025] [@update2024].
Significant drug interactions include:
Ongoing research aims to optimize levodopa therapy through several approaches:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: